Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07313358
Eligibility Criteria:
Inclusion Criteria:
* Be \> 18 years of age
* Sign an informed consent
* Have a diagnosis of HDV infection with or without compensated cirrhosis
* Having started BLV monotherapy 2mg/day according to the criteria reported in the recent clinical practice guidelines on HDV infection promoted by EASL (EASL CPG 2023)
* Be under effective treatment with nucleoside analogues with HBV-DNA \<20 IU/ml at the time of starting BLV
Exclusion Criteria:
* Decompensated liver disease
* BLV combined with pegIFN
* Past treatment with BLV
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07313358
Study Brief:
Protocol Section:
NCT07313358